4.5 Article

An Fc-Silenced IgG1 Format With Extended Half-Life Designed for Improved Stability

期刊

JOURNAL OF PHARMACEUTICAL SCIENCES
卷 106, 期 4, 页码 1008-1017

出版社

WILEY
DOI: 10.1016/j.xphs.2016.12.023

关键词

developability; IgG antibody; pharmacokinetics; protein aggregation; immunology; thermal analysis; biotechnology; calorimetry (DSC); light scattering (dynamic); Fc-silenced; C(H)2; benign blocker

资金

  1. MedImmune

向作者/读者索取更多资源

Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the C(H)2 domain) can be a reduction in biophysical stability which can correlate with increased aggregation propensity, poor manufacturability, and lower solubility. Herein, we characterize the changes in IgG conformational and colloidal stability when 2 sets of C(H)2 mutations TM (L234F/L235E/P331S) and YTE (M252Y/S254T/ T256E) are combined to generate an antibody format lacking immune receptor binding and exhibiting extended half-life. In addition to significantly lowered thermostability, we observe greater conformational flexibility for TM-YTE in C(H)2, increased self-association, and poorer solubility and aggregation profiles. To improve these properties, we dissected the contributions of individual mutations within TM-YTE on thermostability and substituted destabilizing mutations with new mutations that raise thermostability. One novel combination, FQQ-YTE (L234F/L235Q/K322Q/M252Y/S254T/T256E), had significantly improved conformational and colloidal stability, and was found to retain the same biological activities as TM-YTE (extended half-life and lack of antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity). Our engineering approach offers a way to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据